Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 9610167

Validation and the human element.

R G Kieffer
View original source ↗Export metadata ↓

Abstract

Frequently the steps in the process which involve human intervention are the weak links in the process, the steps representing the highest risk. This is not due to lack of training or motivation of people, but to weaknesses in the design of the process and to the intrinsic error rate of manual operations. Quite often in validation work the human element is ignored while mechanical and technological aspects are studied in great detail. This article will include some examples about what we have learned about risk where human intervention is involved by using Failure Mode Effect Analysis (FMEA) and Process Reengineering methodologies. Furthermore, the implications for training and qualification of people in the validation context will be discussed.

Explore related subjects

Drug IndustryPharmaceutical PreparationsQuality ControlJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R G Kieffer. Validation and the human element.. https://pubmed.ncbi.nlm.nih.gov/9610167/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J.

We compared the two commercially available sequencing kits for HIV-1 drug resistance testing, the ViroSeq Genotyping System (Applied Biosystems, Foster City, CA, U.S.A.) and the TRUGENE HIV-1 Genotyping Kit (Visible Genetics, Inc., Toronto, Ontario, Canada), with our in-house genotyping system. Fifteen viral isolates from African patients (6 treated and 9 untreated) covering a panel of HIV-1 subtypes A through J and 7 plasma samples from Belgian and African patients (2 treated and 5 untreated) were tested. All the samples could be amplified and sequenced by the three systems; however, for all systems, alternative amplification/sequencing primers had to be used for some samples belonging to subtype B as well as to other subtypes. The consensus sequence was partially derived from only one strand for the in-house system and for the ViroSeq Genotyping System. The TRUGENE HIV-1 Genotyping Kit scored the highest number of ambiguities, followed by the ViroSeq Genotyping System and the in-house system. For 11 samples, these differences in reporting mixtures affected 14 resistance-related positions, which altered the interpretation toward protease inhibitors for 2 samples when using version 1.2 RetroGram software (Virology Networks, Utrecht, The Netherlands). All three systems were able to sequence diluted samples with a viral load down to 10 3 or 10 4 RNA copies/ml. Our data therefore suggest that the performance of amplification and sequencing primers must be improved to allow fast and reliable resistance testing for all HIV-1 subtypes.

Drug Industry↗